Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
Status:
Completed
Trial end date:
2017-03-09
Target enrollment:
Participant gender:
Summary
This is a multi-site, double-blinded, two-arm, two:one, randomized, trial comparing the
safety of an intramuscular (IM) injection of TMC278 LA to a placebo given once every eight
weeks over a 40 week period among sexually active, HIV- uninfected women.
Phase:
Phase 2
Details
Lead Sponsor:
PATH
Collaborators:
Bill and Melinda Gates Foundation National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH)